Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM | COSTEM 2021: highlights from day one

Arnon Nagler • 21 Oct 2021
COSTEM
General Lymphoma Multiple Myeloma Non-Hodgkin Lymphoma

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses highlights from day one of the COSTEM 2021 meeting, highlighting progress in the haploidentical transplant setting, in the treatment of chronic graft-versus-host disease (GvHD), and in the use of immunotherapies. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.

More from Arnon Nagler

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:21
Trends in alloSCT for good-risk AML: a longitudinal study
Arnon Nagler • 9 Dec 2023
2:15
GvHD prophylaxis post-alloSCT: PTCy versus ATG
Arnon Nagler • 9 Dec 2023
2:13
Haploidentical SCT for the treatment of secondary AML
Arnon Nagler • 9 Dec 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals